Skip to main content
ENDO 2026 Main banner

Adipose Tissue_Appetite_and Obesity

MTP27 - Post-GLP-1: Preparing Patients for Long-Term Maintenance and Transition

Monday, June 15, 2026
9:30 AM - 10:10 AM CT
Location: Room W375B

    Meet the Professor Speaker(s)

  • W Timothy Garvey, MD

    Butterworth Endowed Professor and University Professor
    University of AL - Birmingham
    Birmingham, AL, United States

Disclosure(s):
W Timothy Garvey, MD: .NovoNordisk: Advisory Board (), Clinical Trial Investigator (); AbbVie: Advisory Board (); Boehringer-Ingelheim: Advisory Board (); Corcept Therapeutics: Advisory Board (); Eli Lilly & Company: Advisory Board (), Clinical Trial Investigator (); Fractyl Health: Advisory Board (); Gan & Lee: Advisory Board (); Graviton Biosciences: Advisory Board (); i2o Therapeutics: Advisory Board (); Kaleira: Clinical Trial Investigator (); Keros Therapeutics: Advisory Board (); Madrigal: Advisory Board (); Neurocrine Biosciences: Advisory Board (); Pfizer: Advisory Board (); Regeneron: Advisory Board (); Roche Pharmaceuticals: Advisory Board (), Clinical Trial Investigator (); TERNS Pharmaceuticals: Advisory Board (), Clinical Trial Investigator (); Viking Therapeutics: Clinical Trial Investigator (); Zealand: Advisory Board (), Clinical Trial Investigator ()

Learning Objectives:

  • Describe practices at each phase of obesity management, namely pretreatment, weight reduction, and chronic care, that promote long-term adherence to an individualized therapeutic plan.
  • Explain how a consensus agreement on treatment goals between a patient and a health care professional can be emphasized throughout all phases of obesity management and used to reinforce adherence to long-term therapy.
  • Describe the need to be flexible with dosing and medication selection as needed for long-term maintenance of weight loss and treatment persistence.